A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen.

TitleA randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen.
Publication TypeJournal Article
Year of Publication2010
AuthorsHammer SM, Ribaudo H, Bassett R, Mellors JW, Demeter LM, Coombs RW, Currier J, Morse GD, Gerber JG, Martinez AI, Spreen W, Fischl MA, Squires KE
Corporate AuthorsAIDS Clinical Trials Group(ACTG) 372A Study Team
JournalHIV Clin Trials
Volume11
Issue6
Pagination312-24
Date Published2010 Nov-Dec
ISSN1528-4336
KeywordsAdult, Aged, Anti-HIV Agents, CD4 Lymphocyte Count, Dideoxynucleosides, Double-Blind Method, Drug Therapy, Combination, Female, Genotype, HIV Infections, HIV Protease Inhibitors, HIV-1, Humans, Indinavir, Male, Middle Aged, Placebos, Treatment Failure, Young Adult, Zidovudine
Abstract

BACKGROUND AND OBJECTIVE: Maximizing the durability of viral suppression is a key goal of antiretroviral therapy. The objective of AIDS Clinical Trials Group Study 372A was to determine whether the intensification strategy of adding abacavir to an effective indinavir-dual nucleoside regimen would delay the time to virologic failure.

METHODS: Zidovudine-experienced subjects (n=229) on therapy with indinavir + zidovudine + lamivudine with plasma HIV-1 RNA levels<500 copies/mL were randomized to abacavir 300 mg twice daily or placebo. The primary endpoint was the time to treatment failure, defined as a composite of confirmed virologic failure (2 consecutive HIV-1 RNAs>200 copies/mL) and treatment discontinuation.

RESULTS: At baseline, the study population was 88% male with a median age of 41 years and median CD4 cell count of 250/mm3. Median follow-up was 4.4 years. The primary endpoint was reached in 61/116 of abacavir versus 62/113 of placebo recipients (P=.77); virologic failure occurred in 34/116 and 42/113 patients, respectively (P=.22). There were no differences in the proportions of subjects with plasma HIV-1 RNA levels below 50 copies/mL, in CD4 cell count increases, nor adverse events between the arms. In the study, 17% of subjects developed nephrolithiasis, 2% experienced abacavir hypersensitivity, and 4.8% experienced at least 1 serious cardiovascular event (7 [6%] in the abacavir arm, 4 [3.5%] in the placebo arm). In additional secondary and post hoc analyses, rates of intermittent viremia, suppression below a plasma HIV-1 RNA level of 6 copies/mL, and HIV-1 proviral DNA levels in peripheral blood mononuclear cells were not significantly different in the 2 arms.

CONCLUSIONS: The strategy of intensification with abacavir in patients who are virologically suppressed on a stable antiretroviral regimen does not confer a clinical or virologic benefit. As antiretroviral regimens have become more potent since this trial was completed, it will be even more difficult to prove that late intensification of already virologically suppressed patients will add benefit. However, studies are warranted with drugs with new mechanisms of action to determine whether the level of persistent viremia below 50 copies/ mL can be further reduced and what influence this may have on latent HIV reservoirs.

DOI10.1310/hct1106-312
Alternate JournalHIV Clin Trials
PubMed ID21239359
PubMed Central IDPMC3108099
Grant ListAI 69432 / AI / NIAID NIH HHS / United States
AI-069467 / AI / NIAID NIH HHS / United States
AI-069513 / AI / NIAID NIH HHS / United States
AI025859 / AI / NIAID NIH HHS / United States
AI027661 / AI / NIAID NIH HHS / United States
AI027665 / AI / NIAID NIH HHS / United States
AI027675 / AI / NIAID NIH HHS / United States
AI032782 / AI / NIAID NIH HHS / United States
AI032853 / AI / NIAID NIH HHS / United States
AI045008 / AI / NIAID NIH HHS / United States
AI046370 / AI / NIAID NIH HHS / United States
AI050409 / AI / NIAID NIH HHS / United States
AI058740 / AI / NIAID NIH HHS / United States
AI068636 / AI / NIAID NIH HHS / United States
AI069415 / AI / NIAID NIH HHS / United States
AI069418 / AI / NIAID NIH HHS / United States
AI069419 / AI / NIAID NIH HHS / United States
AI069423 / AI / NIAID NIH HHS / United States
AI069424 / AI / NIAID NIH HHS / United States
AI069428 / AI / NIAID NIH HHS / United States
AI069439 / AI / NIAID NIH HHS / United States
AI069452 / AI / NIAID NIH HHS / United States
AI069465 / AI / NIAID NIH HHS / United States
AI069470 / AI / NIAID NIH HHS / United States
AI069471 / AI / NIAID NIH HHS / United States
AI069472 / AI / NIAID NIH HHS / United States
AI069474 / AI / NIAID NIH HHS / United States
AI069477 / AI / NIAID NIH HHS / United States
AI069484 / AI / NIAID NIH HHS / United States
AI069494-03S1 / AI / NIAID NIH HHS / United States
AI069495 / AI / NIAID NIH HHS / United States
AI069501 / AI / NIAID NIH HHS / United States
AI069511 / AI / NIAID NIH HHS / United States
AI069532 / AI / NIAID NIH HHS / United States
AI069556 / AI / NIAID NIH HHS / United States
AI073961 / AI / NIAID NIH HHS / United States
AI2766 / AI / NIAID NIH HHS / United States
AI50410 / AI / NIAID NIH HHS / United States
AI54907 / AI / NIAID NIH HHS / United States
AI69450 / AI / NIAID NIH HHS / United States
M01 RR000046 / RR / NCRR NIH HHS / United States
M01 RR000046-48 / RR / NCRR NIH HHS / United States
M01 RR005096-17 / RR / NCRR NIH HHS / United States
P30 AI045008 / AI / NIAID NIH HHS / United States
P30 AI045008-11 / AI / NIAID NIH HHS / United States
P30 AI050409 / AI / NIAID NIH HHS / United States
P30 AI050409-11S1 / AI / NIAID NIH HHS / United States
P30 AI050410 / AI / NIAID NIH HHS / United States
P30 AI050410-13 / AI / NIAID NIH HHS / United States
P30 AI054907-05S1 / AI / NIAID NIH HHS / United States
P30 AI073961 / AI / NIAID NIH HHS / United States
P30 AI073961-05 / AI / NIAID NIH HHS / United States
R01 AI058740 / AI / NIAID NIH HHS / United States
R01 AI058740-08 / AI / NIAID NIH HHS / United States
RR 024160 / RR / NCRR NIH HHS / United States
RR-024996 / RR / NCRR NIH HHS / United States
RR00046 / RR / NCRR NIH HHS / United States
RR023561 / RR / NCRR NIH HHS / United States
RR024156 / RR / NCRR NIH HHS / United States
RR025747 / RR / NCRR NIH HHS / United States
RR025780 / RR / NCRR NIH HHS / United States
RR05096 / RR / NCRR NIH HHS / United States
U01 AI025859-18S4 / AI / NIAID NIH HHS / United States
U01 AI027661-19S4 / AI / NIAID NIH HHS / United States
U01 AI027665 / AI / NIAID NIH HHS / United States
U01 AI027665-18S2 / AI / NIAID NIH HHS / United States
U01 AI027675 / AI / NIAID NIH HHS / United States
U01 AI027675-18S2 / AI / NIAID NIH HHS / United States
U01 AI032782-13S3 / AI / NIAID NIH HHS / United States
U01 AI034853 / AI / NIAID NIH HHS / United States
U01 AI034853-12S4 / AI / NIAID NIH HHS / United States
U01 AI046370-05S4 / AI / NIAID NIH HHS / United States
U01 AI068636-06 / AI / NIAID NIH HHS / United States
U01 AI069415-06 / AI / NIAID NIH HHS / United States
U01 AI069418 / AI / NIAID NIH HHS / United States
U01 AI069418-06 / AI / NIAID NIH HHS / United States
U01 AI069419 / AI / NIAID NIH HHS / United States
U01 AI069419-06 / AI / NIAID NIH HHS / United States
U01 AI069423 / AI / NIAID NIH HHS / United States
U01 AI069423-06 / AI / NIAID NIH HHS / United States
U01 AI069424 / AI / NIAID NIH HHS / United States
U01 AI069424-06 / AI / NIAID NIH HHS / United States
U01 AI069428 / AI / NIAID NIH HHS / United States
U01 AI069428-06 / AI / NIAID NIH HHS / United States
U01 AI069432 / AI / NIAID NIH HHS / United States
U01 AI069432-06 / AI / NIAID NIH HHS / United States
U01 AI069439 / AI / NIAID NIH HHS / United States
U01 AI069439-06 / AI / NIAID NIH HHS / United States
U01 AI069450 / AI / NIAID NIH HHS / United States
U01 AI069450-06 / AI / NIAID NIH HHS / United States
U01 AI069452 / AI / NIAID NIH HHS / United States
U01 AI069452-06 / AI / NIAID NIH HHS / United States
U01 AI069465 / AI / NIAID NIH HHS / United States
U01 AI069465-06 / AI / NIAID NIH HHS / United States
U01 AI069467 / AI / NIAID NIH HHS / United States
U01 AI069467-06 / AI / NIAID NIH HHS / United States
U01 AI069470 / AI / NIAID NIH HHS / United States
U01 AI069470-06 / AI / NIAID NIH HHS / United States
U01 AI069471 / AI / NIAID NIH HHS / United States
U01 AI069471-06 / AI / NIAID NIH HHS / United States
U01 AI069472 / AI / NIAID NIH HHS / United States
U01 AI069472-06 / AI / NIAID NIH HHS / United States
U01 AI069474 / AI / NIAID NIH HHS / United States
U01 AI069474-06 / AI / NIAID NIH HHS / United States
U01 AI069477 / AI / NIAID NIH HHS / United States
U01 AI069477-06 / AI / NIAID NIH HHS / United States
U01 AI069484 / AI / NIAID NIH HHS / United States
U01 AI069484-06 / AI / NIAID NIH HHS / United States
U01 AI069494 / AI / NIAID NIH HHS / United States
U01 AI069494-06 / AI / NIAID NIH HHS / United States
U01 AI069495 / AI / NIAID NIH HHS / United States
U01 AI069495-06 / AI / NIAID NIH HHS / United States
U01 AI069501 / AI / NIAID NIH HHS / United States
U01 AI069501-06 / AI / NIAID NIH HHS / United States
U01 AI069511 / AI / NIAID NIH HHS / United States
U01 AI069511-06 / AI / NIAID NIH HHS / United States
U01 AI069513-06 / AI / NIAID NIH HHS / United States
U01 AI069532 / AI / NIAID NIH HHS / United States
U01 AI069532-06 / AI / NIAID NIH HHS / United States
U01 AI069556-06 / AI / NIAID NIH HHS / United States
UL1 RR024156 / RR / NCRR NIH HHS / United States
UL1 RR024156-06 / RR / NCRR NIH HHS / United States
UL1 RR024160 / RR / NCRR NIH HHS / United States
UL1 RR024996 / RR / NCRR NIH HHS / United States
UL1 RR024996-05 / RR / NCRR NIH HHS / United States
UL1 RR025747 / RR / NCRR NIH HHS / United States
UL1 RR025747-04 / RR / NCRR NIH HHS / United States
UL1 RR025780 / RR / NCRR NIH HHS / United States
UL1 RR025780-04 / RR / NCRR NIH HHS / United States
UM1 AI069477 / AI / NIAID NIH HHS / United States
UM1 AI069511 / AI / NIAID NIH HHS / United States